The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Scanlan Sean F. since 2021.
This trader's CIK number is 1856371.
At the time of last reporting, Scanlan Sean F. was the Chief Innovation Officer of Treace Medical Concepts, Inc.. (stock ticker symbol TMCI).
Also see all insider trading activities at Treace Medical Concepts, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | TMCI | 0 | $0 | 50,000 | $398,450 | 83,437 | $76,507 |
| 2024 | TMCI | 0 | $0 | 0 | $0 | 33,750 | $3,273 |
| 2023 | TMCI | 0 | $0 | 75,505 | $1,829,827 | 75,000 | $7,500 |
| 2022 | TMCI | 0 | $0 | 125,000 | $2,635,628 | 125,000 | $131,200 |
| 2021 | TMCI | 0 | $0 | 25,000 | $546,550 | 25,000 | $39,250 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-18 | TMCI | Option Ex | 33,437 | .72 | 24,007 |
| 2025-03-17 | TMCI | Option Ex | 50,000 | 1.05 | 52,500 |
| 2025-03-17 | TMCI | Sale | 50,000 | 7.97 | 398,450 |
| 2024-09-12 | TMCI | Option Ex | 33,750 | .10 | 3,273 |
| 2023-05-16 | TMCI | Option Ex | 25,000 | .10 | 2,500 |
| 2023-05-16 | TMCI | Sale | 25,000 | 25.44 | 635,975 |
| 2023-03-09 | TMCI | Sale | 505 | 24.41 | 12,327 |
| 2023-02-15 | TMCI | Sale | 25,000 | 21.69 | 542,225 |
| 2023-02-15 | TMCI | Option Ex | 25,000 | .10 | 2,500 |
| 2023-01-12 | TMCI | Sale | 25,000 | 25.57 | 639,300 |
| 2023-01-12 | TMCI | Option Ex | 25,000 | .10 | 2,500 |
| 2022-11-14 | TMCI | Option Ex | 25,000 | .10 | 2,500 |
| 2022-11-14 | TMCI | Sale | 25,000 | 24.27 | 606,675 |
| 2022-03-02 | TMCI | Sale | 25,000 | 20.82 | 520,550 |
| 2022-03-02 | TMCI | Option Ex | 25,000 | 1.05 | 26,250 |
| 2022-02-08 | TMCI | Option Ex | 21,127 | 1.05 | 22,183 |
| 2022-02-09 | TMCI | Option Ex | 3,873 | 1.05 | 4,066 |
| 2022-02-08 | TMCI | Sale | 21,127 | 20.02 | 422,899 |
| 2022-02-09 | TMCI | Sale | 3,873 | 20.16 | 78,083 |
| 2022-01-10 | TMCI | Option Ex | 38,862 | 1.57 | 61,013 |
| 2022-01-11 | TMCI | Sale | 8,838 | 20.12 | 177,847 |
| 2022-01-10 | TMCI | Sale | 38,862 | 20.16 | 783,535 |
| 2022-01-11 | TMCI | Option Ex | 8,838 | 1.31 | 11,577 |
| 2022-01-05 | TMCI | Sale | 800 | 20.02 | 16,018 |
| 2022-01-04 | TMCI | Sale | 500 | 20.00 | 10,000 |
| 2022-01-05 | TMCI | Option Ex | 800 | 1.57 | 1,256 |
| 2022-01-03 | TMCI | Sale | 1,000 | 20.02 | 20,021 |
| 2022-01-04 | TMCI | Option Ex | 500 | 1.57 | 785 |
| 2022-01-03 | TMCI | Option Ex | 1,000 | 1.57 | 1,570 |
| 2021-11-10 | TMCI | Option Ex | 25,000 | 1.57 | 39,250 |
| 2021-11-10 | TMCI | Sale | 25,000 | 21.86 | 546,550 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Scanlan Sean F. (Chief Innovation Officer of Treace Medical Concepts, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.